Trulieve Posts Profitable Q1 2026 With $287M Revenue and 35% EBITDA

The cannabis industry's first reporting season under Schedule III is starting to land, and the early signal from the country's largest multi-state operator is the kind of headline cannabis investors have been waiting years for. Trulieve Cannabis Corp. (TCNNF) reported first-quarter 2026 revenue of $287 million, a 59% gross margin, GAAP net income attributable to common shareholders of $2 million, and adjusted EBITDA of $100 million at a 35% margin. After more than half a decade of compressed economics dominated by the federal 280E tax penalty, the print marks one of the cleanest profitable quarters a U.S. MSO has produced, and it sets a benchmark for how the rest of the sector's Q1 earnings calendar should be read.

The Numbers Behind the Headline

The top-line figure is one piece of the story, but the cash and margin profile is what matters for long-term investors. Trulieve generated $56 million in cash flow from operations and $42 million in free cash flow during the quarter, ending the period with $353 million in cash on the balance sheet. A 59% gross margin in a sector that has historically operated in the high-40s is a meaningful step up, and a 35% adjusted EBITDA margin puts Trulieve in the same general profitability tier as well-run consumer packaged goods companies.

The dispensary count tells the rest of the story. Trulieve operates 240 retail dispensaries and more than four million square feet of cultivation and processing capacity across the United States, making it the largest U.S. MSO by store count. That footprint, anchored historically in Florida and extended through targeted acquisitions in Pennsylvania, Maryland, Ohio, and a handful of newer markets, gives the company unusually deep penetration in the medical states that are most directly benefiting from Schedule III.

Why Schedule III Changed the Earnings Math

The April 2026 DOJ order that placed state-licensed medical cannabis operators under Schedule III is the single largest variable in this earnings cycle. Schedule III status removes most state-licensed medical operations from the reach of Internal Revenue Code Section 280E, the provision that has historically forced cannabis sellers to pay federal income tax on gross profit rather than net income. For operators with thin margins, 280E was the difference between profitability and red ink. With 280E relief now applying to qualifying medical operations from January 1, 2026 forward, MSOs are recasting their effective tax rates, and the cash generation that used to disappear into the IRS is finally hitting the bottom line.

Trulieve's results capture the shift in real numbers. The company has also moved aggressively on the administrative side, filing DEA registration applications for 206 of its retail locations to operate under the new federal framework — an unusually proactive step that signals management's bet that Schedule III is sticky. Attorney General Blanche has announced an expedited administrative process to consider broader rescheduling, with a hearing scheduled to begin June 29, 2026, but in the meantime, the medical Schedule III shift is already changing operating economics.

What This Means for the Cannabis Stocks Trade

Cannabis equities had a complicated 2025, with the sector running hard on rescheduling optimism, giving back gains as the timeline slipped, then catching a bid again as the DOJ moved. Heading into Q1 2026 prints, MSO valuations were sitting at median EV/EBITDA multiples in the mid-single digits — cheap by almost any cross-sector benchmark, particularly for businesses now posting margins above 25% on free cash flow that is finally untaxed by 280E for medical operations.

Trulieve's print is the bull case in one slide. It shows that the largest U.S. operator can generate genuine free cash flow, hold $350M+ of cash, and grow margin even as wholesale flower prices remain pressured in mature markets. It does not, however, mean every MSO is about to print the same way. Companies with heavy adult-use exposure — Michigan and California operators in particular — are still wrestling with falling wholesale prices, state-level tax hikes (Michigan's 24% wholesale tax took effect January 1, 2026 and helped drive recreational sales down 8.2% year-over-year in January), and licensing oversupply that crushes price per gram.

The Bigger MSO Picture

Other Q1 2026 results have come in alongside Trulieve's print. Cronos Group posted first-quarter net revenue of $45.2 million, up 40% year-on-year, with net income of $15.7 million — a record quarter for the company. MariMed and other smaller operators are also reporting through May 2026, and the broader pattern is positive for medically focused operators while remaining mixed for those concentrated in compressed adult-use markets.

At the same time, class action litigation against Cresco Labs, Green Thumb Industries, Verano Holdings, and Curaleaf alleging false medical claims about certain products is a reminder that the regulatory environment around cannabis marketing is tightening even as the macro picture brightens. Investors who pile into MSOs on rescheduling optimism still need to read each operator's footnotes carefully.

What to Watch Next

Three things will define the rest of the year for cannabis equity investors. First, the June 29 DEA administrative hearing on broader rescheduling will set the tone for whether Schedule III expands beyond state-licensed medical operations to cover adult-use and the broader supply chain. Second, the next two quarters of MSO earnings will show whether 280E relief is being passed through to bottom-line earnings consistently, or whether companies use the windfall to chase acquisitions and capacity. Third, the SAFER Banking Act and any successor legislation in Congress will determine whether banking and capital markets access continues to normalize, which is the single biggest unlock left for cannabis valuations.

For Trulieve specifically, the questions to ask on subsequent calls are whether the 59% gross margin is structural or partially attributable to one-time mix benefits, how aggressively management plans to convert the $42 million in free cash flow into store expansion versus debt reduction, and how the company's exposure to adult-use Florida — a state where ballot initiatives have repeatedly failed — evolves through 2026.

What the Numbers Mean for Consumers

Investor headlines aside, what this kind of earnings print actually means for cannabis consumers is more competition. When MSOs return to genuine profitability, they tend to invest in store remodels, product innovation, loyalty programs, and price competition. The 280E penalty had effectively functioned as a hidden consumer tax for years — operators built it into shelf pricing because they had no choice. As the penalty lifts for medical operations, the patients shopping medical markets should expect more aggressive pricing and richer rewards programs in the second half of 2026.

Key Takeaways

• Trulieve reported Q1 2026 revenue of $287 million, 59% gross margin, GAAP net income of $2 million, and adjusted EBITDA of $100 million.
• Cash flow from operations was $56 million with $42 million in free cash flow; cash on hand ended the quarter at $353 million.
• The company operates 240 dispensaries and over 4 million square feet of cultivation across the United States.
• Schedule III status for state-licensed medical cannabis is the single biggest variable lifting MSO earnings in 2026.
• The June 29, 2026 DEA administrative hearing on broader rescheduling is the next key catalyst for cannabis equities.

Explore cannabis news, find dispensaries, and join the community at Budpedia.